Eur Rev Med Pharmacol Sci 2024; 28 (6): 2217-2223
DOI: 10.26355/eurrev_202403_35726

Predictive analysis of severe hypocalcemia following total parathyroidectomy for renal secondary hyperparathyroidism

T. Bi, S.-J. Bai, G.-M. Cheng, X.-D. Feng, W. Zhang

Department of Hepatobiliary Pancreatic Spleen Thyroid Surgery, General Hospital of Northern Theater Command, Shenyang, Liaoning, China. 18741658267@163.com


OBJECTIVE: This study aimed to evaluate the incidence and identify risk factors for severe hypocalcemia following total parathyroidectomy (TPTX) in patients with renal secondary hyperparathyroidism (SHPT).

PATIENTS AND METHODS: We included patients undergoing maintenance hemodialysis or peritoneal dialysis who underwent TPTX from January 1, 2018, to April 30, 2023. Participants were categorized into groups based on postoperative corrected serum calcium levels: severe hypocalcemia (<1.8 mmol/L) and non-severe hypocalcemia (≥1.8 mmol/L). We conducted univariate analyses of demographic and laboratory data to identify potential risk factors, which were further analyzed using a binary logistic regression model.

RESULTS: Significant associations were observed with age, dialysis duration exceeding five years, type of dialysis (peritoneal dialysis), lower preoperative corrected serum calcium, elevated preoperative intact parathyroid hormone (iPTH), and increased preoperative alkaline phosphatase (ALP) levels (all p<0.05). Age, preoperative iPTH, and ALP levels were identified as independent risk factors for severe hypocalcemia post-TPTX.

CONCLUSIONS: Younger patients with renal SHPT who have elevated preoperative iPTH and ALP levels are at an increased risk of experiencing severe hypocalcemia following TPTX. These findings underscore the importance of careful preoperative assessment and monitoring to mitigate the risk of this complication.

Free PDF Download

To cite this article

T. Bi, S.-J. Bai, G.-M. Cheng, X.-D. Feng, W. Zhang
Predictive analysis of severe hypocalcemia following total parathyroidectomy for renal secondary hyperparathyroidism

Eur Rev Med Pharmacol Sci
Year: 2024
Vol. 28 - N. 6
Pages: 2217-2223
DOI: 10.26355/eurrev_202403_35726